Biotech Values

[jbog]

We have to keep in mind that Enanta is not following the norm when it comes to small bio research. By far, the majority of bio's of similar size would partner prior to patient trials so they could share the cost and risk. For Enta to develop a drug and then hoping a partner comes along is not good business. They should be negotiating what a partner wants and set the appropriate targets.